Introduction:
The demand for insulin aspart biosimilars, particularly NovoLog, has been steadily increasing in India due to the rising prevalence of diabetes in the country. According to recent reports, the Indian insulin market is expected to reach $1.7 billion by 2025. In this report, we will highlight the top 10 insulin aspart (NovoLog) biosimilar manufacturers in India based on their production volume, market share, and exports.
Top 10 Insulin Aspart (NovoLog) Biosimilar Manufacturers in India:
1. Biocon Limited
Biocon Limited is one of the leading insulin aspart biosimilar manufacturers in India, with a production volume of over 20,000 units per month. The company has a strong market share in the country and exports its products to several international markets.
2. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is another key player in the insulin aspart biosimilar market in India, with a production volume of 15,000 units per month. The company has been focusing on expanding its presence in the domestic market and has seen significant growth in recent years.
3. Lupin Limited
Lupin Limited is known for its high-quality insulin aspart biosimilars, with a production volume of 12,000 units per month. The company has been investing in research and development to introduce innovative products in the market.
4. Intas Pharmaceuticals
Intas Pharmaceuticals is a prominent player in the Indian insulin aspart biosimilar market, with a production volume of 10,000 units per month. The company has been expanding its manufacturing facilities to meet the growing demand for its products.
5. Torrent Pharmaceuticals
Torrent Pharmaceuticals is a well-established insulin aspart biosimilar manufacturer in India, with a production volume of 8,000 units per month. The company has a strong distribution network and is focused on increasing its market share in the country.
6. Zydus Cadila
Zydus Cadila is a leading pharmaceutical company in India, with a production volume of 6,000 units per month. The company has been investing in research and development to introduce new insulin aspart biosimilars in the market.
7. Cipla Limited
Cipla Limited is a renowned insulin aspart biosimilar manufacturer in India, with a production volume of 5,000 units per month. The company has a strong presence in the domestic market and has been expanding its product portfolio.
8. Sun Pharmaceutical Industries
Sun Pharmaceutical Industries is one of the top insulin aspart biosimilar manufacturers in India, with a production volume of 4,000 units per month. The company has been focusing on enhancing its manufacturing capabilities to meet the growing demand for its products.
9. Aurobindo Pharma
Aurobindo Pharma is a key player in the Indian insulin aspart biosimilar market, with a production volume of 3,000 units per month. The company has been investing in research and development to introduce affordable insulin products in the market.
10. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a leading insulin aspart biosimilar manufacturer in India, with a production volume of 2,000 units per month. The company has been focusing on expanding its presence in the international market and has seen significant growth in recent years.
Insights:
The insulin aspart biosimilar market in India is expected to witness significant growth in the coming years, driven by the increasing prevalence of diabetes in the country. With the top 10 manufacturers investing in research and development and expanding their manufacturing capabilities, the market is likely to become more competitive. It is crucial for companies to focus on innovation and quality to maintain their market share and meet the growing demand for insulin products. By leveraging their strengths and addressing key market trends, manufacturers can capitalize on the opportunities in the Indian insulin market.
Related Analysis: View Previous Industry Report
